Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
Rallie McAllister, MD, MPH, CBR Spokesperson and Co-author of The Mommy MD Guides, discusses the limitless possibilities offered by cord blood banking. Regenerative medicine, in particular, is a…
Cord blood contains a plethora of stem cells with the potential for healing and regeneration. But what are the advantages of using cord blood stem cells over other…
Many patients do not know about the uses and potential of umbilical cord blood. Rallie McAllister, MD, MPH, CBR Spokesperson and Co-author of The Mommy MD Guides, discusses…
The Women’s Health Initiative launched a hormone therapy trial in the 1990s and follow-up continued with the women participating in the trials. A new study describes the long-term…
NEW YORK (Reuters Health) – In a phase III, multinational study of patients with heavily pretreated metastatic breast cancer, adding sunitinib to capecitabine provided no benefit, and in…
NEW YORK (Reuters Health) – The results of a phase III Italian study indicate that the risk of breast cancer in postmenopausal women who use hormone replacement therapy…
By Andrew M. Seaman NEW YORK (Reuters Health) – Low-dose aspirin, even if not taken daily, may reduce a woman’s risk of colon cancer over the long term,…
NEW YORK (Reuters Health) – Physicians caring for women who are at increased risk for breast cancer should discuss with them the risks and benefits of specific chemoprevention…
NEW YORK (Reuters Health) – The cumulative incidence of osteonecrosis of the jaw was about 2% over 6 years among women with early breast cancer who received intensive…
By David Douglas NEW YORK (Reuters Health) – Dual HER2 blockade didn’t increase heart problems in a meta-analysis of data from patients with HER2-positive breast cancer. “The combination…
